Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 3Oligodendroglioma 2Astrocytoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Proliferative Breast Disease 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Optic Nerve Glioma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Ependymoma 1Childhood Brain Neoplasm 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Asymptomatic 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × Dynamic Contrast Enhanced Magnetic Resonance Imaging × Clear all
NCT01221506 2020-03-26

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡